SOUTH SAN FRANCISCO,
Sept. 20, 2021 /PRNewswire/ --
Vaxart, Inc. (NASDAQ: VXRT) today announced that Chief
Executive Officer Andrei Floroiu and Chief Scientific
Officer Dr. Sean Tucker will
present at the 2021 Cantor Virtual Global Healthcare
Conference at 10:40 a.m. ET on
Thursday, September 30, 2021.
The presentation will be available by clicking
here and on Vaxart's website. The Company will
also participate in one-on-one meetings during the
conference.
Vaxart's oral tablet COVID-19 vaccine is "The Pill that
Moves the Needle" and the only oral COVID-19
vaccine whose potential is backed by clinical data.
The Company's oral tablet COVID-19
vaccine candidate has completed phase I trials and will
enter phase II clinical trials this year.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a
range of oral recombinant vaccines based on its proprietary
delivery platform. Vaxart vaccines are designed to be administered
using tablets that can be stored and shipped without refrigeration
and eliminate the risk of needle-stick injury. Vaxart believes that
its proprietary tablet vaccine delivery platform is suitable to
deliver recombinant vaccines, positioning the company to develop
oral versions of currently marketed vaccines and to design
recombinant vaccines for new indications. Vaxart's development
programs currently include tablet vaccines designed to protect
against coronavirus, norovirus, seasonal influenza, and respiratory
syncytial virus (RSV), as well as a therapeutic vaccine for human
papillomavirus (HPV), Vaxart's first immuno-oncology indication.
Vaxart has filed broad domestic and international patent
applications covering its proprietary technology and creations for
oral vaccination using adenovirus and TLR3 agonists.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release
regarding Vaxart's strategy, prospects, plans and objectives,
results from pre-clinical and clinical trials, commercialization
agreements and licenses, and beliefs and expectations of management
are forward-looking statements. These forward-looking statements
may be accompanied by such words as "should," "believe," "could,"
"potential," "will," "expected," "plan," and other words and terms
of similar meaning. Examples of such statements include, but are
not limited to, statements relating to the receipt by Vaxart's
ability to develop and commercialize its product candidates,
including its vaccine booster products; Vaxart's expectations
regarding clinical results and trial data; and Vaxart's
expectations with respect to the effectiveness of its product
candidates. Vaxart may not actually achieve the plans, carry out
the intentions, or meet the expectations or projections disclosed
in the forward-looking statements, and you should not place undue
reliance on these forward-looking statements. Actual results or
events could differ materially from the plans, intentions,
expectations, and projections disclosed in the forward-looking
statements. Various important factors could cause actual results or
events to differ materially from the forward-looking statements
that Vaxart makes, including uncertainties inherent in research and
development, including the ability to meet anticipated clinical
endpoints, commencement, and/or completion dates for clinical
trials, regulatory submission dates, regulatory approval dates,
and/or launch dates, as well as the possibility of unfavorable new
clinical data and further analyses of existing clinical data; the
risk that clinical trial data are subject to differing
interpretations and assessments by regulatory authorities;
whether regulatory authorities will be satisfied with the
design of and results from the clinical studies; decisions by
regulatory authorities impacting labeling, manufacturing processes,
and safety that could affect the availability or commercial
potential of any product candidate, including the possibility that
Vaxart's product candidates may not be approved by the FDA or
non-U.S. regulatory authorities; that, even if approved by the FDA
or non-U.S. regulatory authorities, Vaxart's product candidates may
not achieve broad market acceptance; that a Vaxart collaborator may
not attain development and commercial milestones; that Vaxart or
its partners may experience manufacturing issues and delays due to
events within, or outside of, Vaxart's or its partners' control;
difficulties in production, particularly in scaling up initial
production, including difficulties with production costs and
yields, quality control, including stability of the product
candidate and quality assurance testing, shortages of qualified
personnel or key raw materials, and compliance with strictly
enforced federal, state, and foreign regulations; that Vaxart may
not be able to obtain, maintain, and enforce necessary patent and
other intellectual property protection; that Vaxart's capital
resources may be inadequate; Vaxart's ability to resolve pending
legal matters; Vaxart's ability to obtain sufficient capital to
fund its operations on terms acceptable to Vaxart, if at all; the
impact of government healthcare proposals and policies; competitive
factors; and other risks described in the "Risk Factors" sections
of Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart
does not assume any obligation to update any forward-looking
statements, except as required by law.
View original
content:https://www.prnewswire.com/news-releases/vaxart-to-present-at-the-2021-cantor-virtual-global-healthcare-conference-on-thursday-september-30-301379879.html
SOURCE Vaxart, Inc.